June 2026 Research Update

Adults with hypophosphatasia (HPP) can have a substantial day-to-day burden even when their HPP is not mainly showing up as bone problems. In a US registry comparison, pain and muscle symptoms were frequent in both skeletal and non-skeletal forms, and average quality-of-life and function scores were similar across the groups. This month adds a clearer picture that the absence of obvious skeletal involvement does not necessarily mean the condition is "mild" in how it feels. [1]

The same registry analysis also showed that skeletal HPP came with a higher rate of certain specific problems, especially dental issues, abnormal gait, nerve-related symptoms, and use of mobility aids. At the same time, the two groups looked similar on broad measures like a walking test and questionnaires about pain, disability, and health-related quality of life. This combination helps explain why two people can have different visible features of HPP but still report a similar overall impact on daily life. [1]

Genetic testing in the registry participants found disease-causing ALPL variants in most people in both the skeletal and non-skeletal groups. In plain language, this supports that many adults with symptoms consistent with HPP also have a genetic finding that fits the diagnosis, even when their symptoms are not primarily skeletal. It also highlights that HPP can show up in different ways while still sharing a similar genetic root. [1]

For patients and caregivers, this month mainly adds reassurance that non-skeletal HPP symptoms are recognized and measurable in large groups, not just in individual stories. The evidence here is from routine registry data, so it describes patterns rather than proving why symptoms happen or predicting what will happen to any one person. What remains uncertain is how these group averages translate into personal prognosis, since people can vary widely. This matters most for understanding and communication now, and may guide future research on how to measure burden beyond bone findings. [1]

A small real-world case series reported that adults with childhood-onset HPP who began asfotase alfa (an enzyme replacement therapy) experienced improvements that mattered in daily life, such as walking ability and independence. Across the three people described, pain tended to lessen and function tended to improve, alongside reported improvements in bone-related findings. This month adds supportive but early human evidence that benefits seen with this therapy can also be described when treatment starts in adulthood for pediatric-onset disease. [2]

The cases described changes like improved mobility measures (including a 6-minute walk distance reported for one person), fewer limitations such as wheelchair use, and better participation in everyday activities like working. Some people also had improvements reported in sleep quality or breathing-related symptoms, though details differed by person. Because this is a small case series without a comparison group, it cannot show how consistently these changes happen across the wider HPP community. [2]

Treatment was generally described as well tolerated in these cases, with one report of brief diarrhea. The authors also noted that some standard bone density tests can be hard to interpret in HPP, which is a reminder that people may track progress using multiple kinds of information, not a single scan or number. This helps explain why reports often combine imaging, symptoms, and functional measures when describing response. [2]

For patients, this evidence is early and based on only three individuals, but it gives concrete examples of the kinds of improvements some adults reported after starting asfotase alfa, especially around pain and mobility. It does not establish how likely these outcomes are, how quickly they occur for most people, or which patients benefit most, because there was no control group and follow-up was not standardized. This matters mainly as context and expectation-setting for research discussions, and it supports the need for larger, more consistent real-world tracking in adults treated later in life. [2]

This month included several studies focused on what ALPL genetic findings mean outside of classic bone symptoms, especially in counseling and dental presentations. Taken together, they show that genetics can be informative but also complicated, because the same gene can appear in very different real-life situations. The new information here is less about treatment and more about how people understand results, how families notice symptoms, and how dental findings may fit into the HPP spectrum. [3] [4] [5]

In a survey of 30 people identified as ALPL heterozygotes through reproductive carrier screening, most said they were glad HPP was included and that the counseling explanation was easy to understand. People who felt more empowered also reported taking more follow-up actions and were more likely to report HPP-related symptoms in family members, while satisfaction was lower when results felt burdensome. This adds a patient-centered view that learning about ALPL status can prompt action and questions, but can also feel stressful depending on how the information lands. [3]

A family case report described odonto-HPP (a mainly dental form of HPP) alongside tooth agenesis, meaning some teeth never formed. Genetic testing found two new ALPL missense variants, and the authors did not find disease-causing variants in the genes they checked that are usually linked to tooth agenesis. This report raises the possibility that, in some families, ALPL changes could be part of a broader dental pattern than traditionally recognized, but it remains a single-family observation. [4]

Another case report involved an infant with osteogenesis imperfecta (OI) type 4 who also carried a heterozygous ALPL variant associated with HPP. The authors reported that the ALPL carrier state did not appear to change the OI course in this child and family, who had improvement over time and did not show fractures or early tooth loss during follow-up. This adds a cautious note that having an ALPL variant alongside another bone condition does not automatically mean symptoms will be worse, at least in this one family. [5]

For patients and caregivers, these studies mainly matter for understanding how genetic information can affect real life now, including emotions, family conversations, and attention to dental signs. The survey evidence suggests many people appreciate clear counseling, but the same results can feel burdensome for others, and follow-up actions varied widely. The case reports add possibilities to watch for in research, such as a link between ALPL variants and missing teeth in some families, while also showing that an ALPL carrier state may not always change the course of another bone disease. What remains uncertain is how often these patterns apply beyond the specific families described, so much of this should be viewed as early information rather than a general rule. [3] [4] [5]

A laboratory mouse study suggested that HPP may change how jawbone reacts to mechanical pressure, even when the visible amount of tooth movement is similar. In a mild HPP model, tooth movement distance did not differ from normal mice, and common blood markers of bone turnover were also similar. What became clearer this month is that local bone changes in the jaw may still be different under force, which could matter for dental research in HPP. [6]

When orthodontic force was applied, the HPP-model mice showed more bone resorption on the compressed side of the jaw and lower bone quality in that area. The researchers also observed more osteoclasts, which are cells that break down bone, and fibrous tissue in resorption sites. This points to altered bone remodeling in the jaw under load, but it is animal research and does not directly predict what will happen in patients. [6]

For patients, this is early, preclinical evidence that may help explain why dental and jaw issues can be part of HPP, especially when teeth and bone are under mechanical stress. It does not provide direct answers about orthodontics or dental procedures in people, because mice are not the same as humans and the study looked at short-term changes. What it adds now is a clearer research direction: local jawbone responses may differ in HPP even when broader measures look similar. This may matter later if human studies confirm similar patterns. [6]